TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16781588

Group type: EXPERIMENTAL
Intervention: EPs 7630 (30 drops three times daily for seven days)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo (30 drops three times daily for seven days)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: EPs 7630
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 12137074

Group type: EXPERIMENTAL
Intervention: Postoperative interdisciplinary care
Number of subjects: 279

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 279
Study: 10053226

Group type: EXPERIMENTAL
Intervention: Selegiline
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 7475819

Group type: EXPERIMENTAL
Intervention: GPi pallidotomy
Number of subjects: 14
Study: 2253927

Group type: EXPERIMENTAL
Intervention: Furazolidone 0.1g t.i.d.
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Metronidazole 0.2g t.i.d.
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 6106612

Group type: EXPERIMENTAL
Intervention: Halazepam 120 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Halazepam 60 mg
Number of subjects: 0
Study: 31157583

Group type: EXPERIMENTAL
Intervention: T‐DM1+P
Number of subjects: 444

Group type: COMPARATOR
Intervention: TCH+P
Number of subjects: 444
Study: 28241328

Group type: EXPERIMENTAL
Intervention: Spencer technique
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 15
Study: 25351610

Group type: EXPERIMENTAL
Intervention: LMWH
Number of subjects: 121

Group type: COMPARATOR
Intervention: UFH
Number of subjects: 121
Study: 23276482

Group type: EXPERIMENTAL
Intervention: Risperidone long-acting injectable (RLAI)
Number of subjects: 323
Study: 21434337

Group type: EXPERIMENTAL
Intervention: Nuanxin Capsule (NXC)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 19376452

Group type: EXPERIMENTAL
Intervention: Calcium dobesilate (1500 mg per day)
Number of subjects: 635

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 635
Study: 19839182

Group type: EXPERIMENTAL
Intervention: Pravastatin-acetylsalicylic acid combination
Number of subjects: 5

Group type: COMPARATOR
Intervention: Pravastatin alone
Number of subjects: 5
Study: 15117729

Group type: EXPERIMENTAL
Intervention: NFEV(1) (FEV(1) corrected for gas compression)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FEV(1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NFEV(1)
Number of subjects: 0
Study: 11920767

Group type: EXPERIMENTAL
Intervention: 17-beta-estradiol matrix patch (first patch worn for 4 days, second for 3 days, third for 4 days)
Number of subjects: 16

Group type: COMPARATOR
Intervention: 17-beta-estradiol matrix patch (control group without E(2) pretreatment)
Number of subjects: 16
Study: 9672184

Group type: EXPERIMENTAL
Intervention: Recombinant interferon-alpha2a (with or without ribavirin)
Number of subjects: 3
Study: 8004359

Group type: COMPARATOR
Intervention: Ofloxacin (200 mg) alone
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 mg) with Sho‐saiko‐to (TJ‐9)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 mg) with Rikkunshi‐to (TJ‐43)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 mg) with Sairei‐to (TJ‐114)
Number of subjects: 7
Study: 2620951

Group type: EXPERIMENTAL
Intervention: Intramuscular iron-dextran complex
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous iron-dextran complex
Number of subjects: 0
Study: 831964

Group type: EXPERIMENTAL
Intervention: Lumbar epidural analgesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: No regional analgesia (Control)
Number of subjects: 0
Study: 31442535

Group type: EXPERIMENTAL
Intervention: Single-layer deep-dermal suturing technique
Number of subjects: 49

Group type: COMPARATOR
Intervention: Conventional bilayered closure technique
Number of subjects: 49
Study: 28850600

Group type: EXPERIMENTAL
Intervention: Anterior cervical discectomy without fusion
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Fusion by cage standalone
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Disc prosthesis
Number of subjects: 142

Group type: COMPARATOR
Intervention: All treatment groups
Number of subjects: 142
Study: 1533832

Group type: EXPERIMENTAL
Intervention: Lumbotrain
Number of subjects: 216

Group type: COMPARATOR
Intervention: Control (standard therapy)
Number of subjects: 216
Study: 22882007

Group type: EXPERIMENTAL
Intervention: Subconjunctival 1.25 mg/0.05 mL of bevacizumab at the end of surgery (Group 2)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Pterygium excision with conjunctivo‐limbal autograft (Group 1)
Number of subjects: 41
Study: 20511258

Group type: EXPERIMENTAL
Intervention: Opiates
Number of subjects: 1052

Group type: COMPARATOR
Intervention: Nitrates
Number of subjects: 1052

Group type: COMPARATOR
Intervention: Diuretics
Number of subjects: 1052
Study: 18194593

Group type: EXPERIMENTAL
Intervention: Low-dose medical food emulsion (0.75 g GLA + 0.5 g EPA)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: High-dose medical food emulsion (1.13 g GLA + 0.75 g EPA)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Low-dose medical food emulsion (EFF1009)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo emulsion
Number of subjects: 100
Study: 16407665

Group type: EXPERIMENTAL
Intervention: Intravenous prednisolone (1 approximately 3 mg/kg/day for 3 days)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no intravenous prednisolone)
Number of subjects: 62
Study: 12888140

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0
Study: 10569964

Group type: EXPERIMENTAL
Intervention: 6 feeds of cows' milk per day
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: 12 feeds of cows' milk per day
Number of subjects: 262

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 262
Study: 8912147

Group type: EXPERIMENTAL
Intervention: Torasemide (40 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Furosemide (80 mg)
Number of subjects: 18
Study: 1756847

Group type: EXPERIMENTAL
Intervention: Clemastine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6337700

Group type: EXPERIMENTAL
Intervention: Intravesical BCG (120 mg in 50 ml saline) administered weekly for 6 weeks
Number of subjects: 69

Group type: COMPARATOR
Intervention: TUR alone (control group)
Number of subjects: 69
Study: 31787586

Group type: EXPERIMENTAL
Intervention: Icosapent ethyl (IPE) 4 g/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29898748

Group type: EXPERIMENTAL
Intervention: One three-hour education course on psychological stresses and management skills
Number of subjects: 290

Group type: COMPARATOR
Intervention: Control arm (no additional education course)
Number of subjects: 290
Study: 26499756

Group type: EXPERIMENTAL
Intervention: Whey isolate protein drink (12.5 g)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Whey isolate protein drink (50 g)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Whey isolate protein drink (75 g)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Whey isolate protein drink (100 g)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Glucose drink (20 g)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (water)
Number of subjects: 27
Study: 24374803

Group type: EXPERIMENTAL
Intervention: Glutamine 0.5 g/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 60

Group type: COMPARATOR
Intervention: 18AA‐II solution
Number of subjects: 60
Study: 22327223

Group type: EXPERIMENTAL
Intervention: Sickle cell trait (HbAS)
Number of subjects: 601
Study: 19019364

Group type: EXPERIMENTAL
Intervention: EUS
Number of subjects: 120

Group type: COMPARATOR
Intervention: ERC
Number of subjects: 120
Study: 17978250

Group type: EXPERIMENTAL
Intervention: Supported employment
Number of subjects: 546

Group type: COMPARATOR
Intervention: Other vocational services
Number of subjects: 546
Study: 16685547

Group type: EXPERIMENTAL
Intervention: Vitamin C (1,000 mg day(-1))
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 15054729

Group type: EXPERIMENTAL
Intervention: Informational self-management intervention (booklet)
Number of subjects: 209

Group type: COMPARATOR
Intervention: No booklet (control group)
Number of subjects: 209
Study: 10781923

Group type: EXPERIMENTAL
Intervention: Ketamine (0.3 mg/kg, Ketalar)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 8834420

Group type: EXPERIMENTAL
Intervention: Buprenorphine (average dose = 9.0 mg/day sublingually)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Methadone (average dose = 54 mg/day orally)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 86

Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 86
Study: 1432467

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (5 mg/kg body weight/day) for 2 weeks
Number of subjects: 301

Group type: COMPARATOR
Intervention: Placebo in multivitamin syrup for 2 weeks
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 301
Study: 3901357

Group type: EXPERIMENTAL
Intervention: Piperacillin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cephalothin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 0
Study: 31107900

Group type: EXPERIMENTAL
Intervention: Behavioral physical activity intervention
Number of subjects: 202
Study: 28135389

Group type: EXPERIMENTAL
Intervention: Weekly telephone intervention problem solving (TIPS)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 105
Study: 25956257

Group type: EXPERIMENTAL
Intervention: Integrated Telemedicine (ITM)
Number of subjects: 566

Group type: COMPARATOR
Intervention: Phone counseling
Number of subjects: 566
Study: 23966217

Group type: EXPERIMENTAL
Intervention: Honey plus coffee (HC)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Systemic steroid (S)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control (C) - Guaifenesin
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Comparison between HC and S
Number of subjects: 97
Study: 21222132

Group type: EXPERIMENTAL
Intervention: Eccentric exercise of the elbow flexors (6 sets of 10 contractions at 120% of voluntary concentric maximum)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Eccentric exercise of the elbow flexors
Number of subjects: 14
Study: 19126319

Group type: EXPERIMENTAL
Intervention: Dilapan-S™ and misoprostol combination
Number of subjects: 25
Study: 17606053

Group type: EXPERIMENTAL
Intervention: 1 injection of injectable mixed subtype collagenase
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 3 injections of injectable mixed subtype collagenase
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Open-label extension phase with injectable mixed subtype collagenase
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Overall treatment with injectable mixed subtype collagenase
Number of subjects: 35
Study: 15478484

Group type: EXPERIMENTAL
Intervention: 5% sodium fluoride (NaF) bioerodible gel
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control gel (no treatment)
Number of subjects: 36
Study: 11513310

Group type: EXPERIMENTAL
Intervention: Total Body Recumbent Stepper (TBRS) training 3 days a week for 12 weeks, intensity progressed from 50% HRRmax for 20 min to 75% HRRmax for 40 min
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Total Body Recumbent Stepper (TBRS) training
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 26
Study: 9633801

Group type: EXPERIMENTAL
Intervention: metoprolol
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: carvedilol
Number of subjects: 24
Study: 8018000

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 1889

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1889

Group type: EXPERIMENTAL
Intervention: Aspirin (75 mg)
Number of subjects: 1889

Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg)
Number of subjects: 1889

Group type: EXPERIMENTAL
Intervention: Aspirin (combined)
Number of subjects: 1889

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 1889
Study: 3111508

Group type: EXPERIMENTAL
Intervention: Alfentanil 10 micrograms kg‐1
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Alfentanil 40 micrograms kg‐1
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Alfentanil 10 micrograms kg‐1 and 40 micrograms kg‐1
Number of subjects: 44

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 44
Study: 31034336

Group type: EXPERIMENTAL
Intervention: Valgus Control Instruction (VCI) exercises
Number of subjects: 64
Study: 29025837

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb12 at a dose of 10^9 colony-forming units, orally, once daily for 6 months.
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo, identically appearing, orally, once daily for 6 months.
Number of subjects: 96
Study: 26009832

Group type: EXPERIMENTAL
Intervention: Early ART (CD4 350‐550)
Number of subjects: 886
Study: 23524153

Group type: EXPERIMENTAL
Intervention: Y‐graft technique
Number of subjects: 90

Group type: COMPARATOR
Intervention: C‐graft technique
Number of subjects: 90
Study: 22164492

Group type: EXPERIMENTAL
Intervention: Capsule Xinganbao
Number of subjects: 118

Group type: COMPARATOR
Intervention: Conventional medicine
Number of subjects: 118
Study: 19840566

Group type: EXPERIMENTAL
Intervention: Bivalirudin monotherapy
Number of subjects: 335

Group type: COMPARATOR
Intervention: UFH plus tirofiban
Number of subjects: 335
Study: 16575284

Group type: EXPERIMENTAL
Intervention: Nurse-led smoking cessation program
Number of subjects: 0
Study: 15474171

Group type: EXPERIMENTAL
Intervention: Finger tapping
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oscillatory motion of the hand
Number of subjects: 0

Group type: COMPARATOR
Intervention: Event‐based timing control (Wing‐Kristoffersson model)
Number of subjects: 0
Study: 12713211

Group type: EXPERIMENTAL
Intervention: After-school intervention focused on increasing physical activity and healthy eating, conducted twice a week for 12 weeks
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group received a program unrelated to nutrition and physical activity over 12 weeks
Number of subjects: 54
Study: 11095423

Group type: EXPERIMENTAL
Intervention: 20 mg PEG‐OB weekly subcutaneous injections
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 8628472

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTXA) 300 units
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTXA)
Number of subjects: 39
Study: 1319187

Group type: EXPERIMENTAL
Intervention: Succinylcholine 1 mg/kg with thiopental sodium, fentanyl, and midazolam, maintained with 70% nitrous oxide in oxygen
Number of subjects: 44

Group type: COMPARATOR
Intervention: End-tidal isoflurane 0.75% to 1% included in the induction regimen
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 1.0 Hz stimulation
Number of subjects: 44

Group type: COMPARATOR
Intervention: 0.1 Hz stimulation
Number of subjects: 44
Study: 2934708

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (4-6 mg/mg/day) introduced at 3rd month after transplantation
Number of subjects: 58

Group type: COMPARATOR
Intervention: Standard treatment (prednisone, azathioprine, and antilymphocyte serum)
Number of subjects: 58
Study: 30900196

Group type: EXPERIMENTAL
Intervention: Ankaferd Blood Stopper (ABS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Dry sterile sponges (Control)
Number of subjects: 80
Study: 29364540

Group type: EXPERIMENTAL
Intervention: Tactile stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: No tactile stimulation (Control)
Number of subjects: 0
Study: 27539508

Group type: EXPERIMENTAL
Intervention: Investigational therapeutics for preventing oxaliplatin-induced neurotoxicity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24713222

Group type: EXPERIMENTAL
Intervention: Palindrome Symmetric Tip Dialysis Catheter
Number of subjects: 302

Group type: COMPARATOR
Intervention: HemoStar Long‐Term Hemodialysis Catheter
Number of subjects: 302
Study: 23059149

Group type: EXPERIMENTAL
Intervention: Wake therapy with bright light therapy and sleep time stabilization
Number of subjects: 75

Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 75
Study: 20639039

Group type: EXPERIMENTAL
Intervention: Transperitoneal laparoscopic pyeloplasty
Number of subjects: 39

Group type: COMPARATOR
Intervention: Open pyeloplasty
Number of subjects: 39
Study: 18759308

Group type: EXPERIMENTAL
Intervention: Pegloticase 8 mg every 2 weeks
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Pegloticase 12 mg every 4 weeks
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Pegloticase 8 mg every 4 weeks
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Pegloticase 4 mg every 2 weeks
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: All dosage groups
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Infusion-day adverse events
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Antipegloticase antibody presence
Number of subjects: 41
Study: 16060412

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS 20 mg
Number of subjects: 264

Group type: COMPARATOR
Intervention: Enalapril 20 mg
Number of subjects: 264
Study: 12136446

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Manualized Psychodynamic Therapy
Number of subjects: 0
Study: 10468098

Group type: EXPERIMENTAL
Intervention: 2 hours of bed rest
Number of subjects: 0

Group type: COMPARATOR
Intervention: 6 hours of bed rest
Number of subjects: 0
Study: 7486839

Group type: EXPERIMENTAL
Intervention: 200 mg added caffeine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (decaffeinated coffee without caffeine)
Number of subjects: 12
Study: 2123395

Group type: COMPARATOR
Intervention: fentanyl 2.5 micrograms kg‐1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: alfentanil 10 micrograms kg‐1
Number of subjects: 40
Study: 6996986

Group type: EXPERIMENTAL
Intervention: Clonidine (Catapresan Depot Perlongetten)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31215092

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (escalating daily doses from 400 to 4800 IU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 0
Study: 28161080

Group type: EXPERIMENTAL
Intervention: Internet-based guided self-help intervention (10 sessions involving psychoeducation, relaxation exercises, sensate focus, and gradual exposure with dilators)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Waitlist control group (WCG)
Number of subjects: 77
Study: 26156272

Group type: EXPERIMENTAL
Intervention: Audiovisual distraction
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Audio distraction
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 24131168

Group type: EXPERIMENTAL
Intervention: Heroin administration
Number of subjects: 28

Group type: COMPARATOR
Intervention: Saline (placebo) administration
Number of subjects: 28
Study: 21725236

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside‐enhanced cardiopulmonary resuscitation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard cardiopulmonary resuscitation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Active compression‐decompression cardiopulmonary resuscitation + impedance threshold device
Number of subjects: 40
Study: 18344024

Group type: COMPARATOR
Intervention: Conventional treatment (three cycles of 3-weekly FEC(100) then three cycles of 3-weekly Doc 100 mg/m(2))
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Dose-dense treatment (four 10- to 11-day cycles of FEC(75) then four 2-weekly cycles of Doc 75 mg/m(2))
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Dose-dense treatment (Doc given after FEC)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Dose-dense treatment
Number of subjects: 117

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 117
Study: 16978370

Group type: EXPERIMENTAL
Intervention: RSGMET (4 mg rosiglitazone / 500 mg metformin, escalated to 8 mg/2 g)
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: RSGMET
Number of subjects: 526

Group type: COMPARATOR
Intervention: MET (500 mg, escalated to 3 g)
Number of subjects: 526

Group type: COMPARATOR
Intervention: MET
Number of subjects: 526
Study: 15325604

Group type: EXPERIMENTAL
Intervention: Open sphincterotomy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Closed sphincterotomy
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Patients with anal fissure before treatment
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Patients cured after 2 years
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Patients with recurrent fissure
Number of subjects: 80
Study: 11843992

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (CIP) oral suspension (250 mg/5 mL twice daily)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Trimethoprim/sulfamethoxazole (TMP/SMX) oral suspension (160/800 mg/20 mL twice daily)
Number of subjects: 261
Study: 9763553

Group type: EXPERIMENTAL
Intervention: Desmopressin (DDAVP)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Factor VIII/von Willebrand factor (FVIII/vWF) concentrate
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High-dose intravenous Ig (IVIg) (1 g/kg/d for 2 days)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Long-term IVIg therapy (repeated single infusions every 21 days)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: IVIg
Number of subjects: 10

Group type: COMPARATOR
Intervention: DDAVP and FVIII/vWF concentrates
Number of subjects: 10
Study: 7852605

Group type: EXPERIMENTAL
Intervention: standard eye movement desensitization (EMD)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: variant of EMD with light tracking task
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: variant of EMD with fixed visual attention
Number of subjects: 23
Study: 3290034

Group type: EXPERIMENTAL
Intervention: 0.5 mg intravenous glucagon (50 patients)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group without glucagon (53 patients)
Number of subjects: 103